Skip to content
Menu

12 Health Care Stocks Moving In Monday's After-Market Session

Benzinga Insights 8 hours ago

Movers

Gainers Dare Bioscience (NASDAQ:DARE) shares rose 9.5% to $0.64 during Monday's after-market session. The company's market cap stands at $12.9 million. As per the press release, Q3 earnings came out today.

Gainers

  • Dare Bioscience (NASDAQ:DARE) shares rose 9.5% to $0.64 during Monday's after-market session. The company's market cap stands at $12.9 million. As per the press release, Q3 earnings came out today.
  • Circle8 Group (NASDAQ:CIRC) stock rose 7.4% to $0.18. The market value of their outstanding shares is at $21.5 million.
  • Azitra (AMEX:AZTR) shares increased by 4.98% to $0.63. The company's market cap stands at $3.6 million. The company's, Q3 earnings came out 2 days ago.
  • Exicure (NASDAQ:XCUR) shares rose 4.67% to $1.12. The market value of their outstanding shares is at $7.0 million.
  • Telomir Pharmaceuticals (NASDAQ:TELO) stock moved upwards by 3.95% to $0.5. The company's market cap stands at $36.1 million.
  • Geovax Labs (NASDAQ:GOVX) stock increased by 3.42% to $2.09. The company's, Q3 earnings came out 2 days ago.

Losers

  • Akanda (NASDAQ:AKAN) shares decreased by 5.9% to $2.08 during Monday's after-market session. The company's market cap stands at $3.5 million.
  • IN8bio (NASDAQ:INAB) stock fell 5.18% to $0.77. The market value of their outstanding shares is at $8.8 million.
  • Omeros (NASDAQ:OMER) shares decreased by 5.1% to $15.83. The company's market cap stands at $1.2 billion. As per the news, the Q3 earnings report came out today.
  • Village Farms Intl (NASDAQ:VFF) shares declined by 4.77% to $2.2. The company's market cap stands at $296.0 million.
  • UroGen Pharma (NASDAQ:URGN) shares declined by 3.96% to $26.99. The company's market cap stands at $1.2 billion.
  • Standard BioTools (NASDAQ:LAB) stock fell 3.23% to $0.6. The company's market cap stands at $279.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Read at benzinga.com